Roche Backs Out Of Daclizumab Transplantation Deal With PDL
This article was originally published in The Pink Sheet Daily
Executive Summary
PDL is moving forward with Phase II development of the biologic in multiple sclerosis with partner Biogen Idec.
You may also be interested in...
PDL BioPharma Seeks Ularitide Partner That Grants Rights To A Late-Stage Drug
A more complicated partnership involving two clinical programs is taking more time to complete than a “ularitide-only” deal, the biotech says.
PDL BioPharma Seeks Ularitide Partner That Grants Rights To A Late-Stage Drug
A more complicated partnership involving two clinical programs is taking more time to complete than a “ularitide-only” deal, the biotech says.
Orphan Therapeutics Acquires Full Rights To Terlipressin From PDL BioPharma
The company will initiate a rolling NDA submission in Q2 2007 despite failure to meet novel primary endpoint, Orphan president tells “The Pink Sheet” DAILY.